- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02007317
Safety and Efficacy of Oshadi D and Oshadi R in Basal Cell Carcinoma Patients Prior to Tumor Excision a Phase 2 Study
April 16, 2018 updated by: Oshadi Drug Administration
A Single Center, Open Label Study for Evaluation of the Safety and Efficacy of Oshadi D and Oshadi R in Patients With Basal Cell Carcinoma (BCC) Prior to Tumor Excision- a Phase II Study
This study is single-arm, none randomized, open label, two-dose-cohorts, single center clinical trial for evaluation of the safety and efficacy of Oshadi D and Oshadi R in patients with BCC.
Patients will receive Oshadi D and Oshadi R for 60 -90 days until the planned surgical excision of the lesion.
Study Overview
Study Type
Interventional
Enrollment (Actual)
30
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Zrifin, Israel
- Assaf-Harofeh Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
21 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age > 21 years old with tissue confirmed diagnosis of local BCC.
- Patient is candidate for surgical excision of the BCC in few months.
- BCC lesion ≥10mm in its longest diameter.
- Sexually active fertile patients and their partners must agree to use medically accepted methods of contraception during therapy and 3 months after the last dose of the study drugs.
- Female patients of childbearing potential must have a negative pregnancy test at screening.
- Patient must understand and be willing to give written informed consent prior to any study procedures or evaluations and be willing to adhere to all study schedules and requirements.
Exclusion Criteria:
- Uncontrolled Intercurrent illness or any history of significant cardiac, renal, neurologic, metabolic, pulmonary, gastrointestinal, hematologic abnormality, chronic hepatic disease or any other disease which in the judgment of the investigator would interfere with the study or confound the results.
- Other active cancer disease.
- Serum creatinine > 1.5 mg/dL for males and >1.4 mg/dL for females.
- Female patient who are breastfeeding or have a positive pregnancy test at screening or at any time during the study.
- Any acute cardiovascular event during the last 6 months prior to inclusion.
- Symptomatic congestive heart failure with ejection fraction < 30%.
- Patient has prothrombin time/International Normalization Ration (PT/INR) or partial thromboplastin time (PTT) test results > 1.3 UNL.
- Hemoglobin ≤ 11 g/dL
- Platelets < 150,000 per microliter
- White blood cell count<3,000 x109/L and/or absolute neutrophils count <1.5 x 109/L
- Significant swallowing disorders.
- History of small bowel surgery.
- Any history of pelvic or abdominal radiation.
- Pre-existing mal-absorption syndrome, irritable bowel syndrome or other clinical situation which could affect oral absorption.
- Mental disorders.
- Inability to give written informed consent.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Oshadi D and Oshadi R
Anti tumor agents
|
Anti tumor agents
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Adverse events and serious adverse events occurence
Time Frame: treatment end (day 60 or 90)
|
treatment end (day 60 or 90)
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The primary efficacy endpoint of this study is Overall Response Rate (ORR)
Time Frame: treatment end (day 60 or 90)
|
treatment end (day 60 or 90)
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To estimate the duration of treatment to achieve response
Time Frame: 9 months
|
To estimate the duration of treatment needed to achieve response
|
9 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Lior Heller, Prof., Assaf Harofeh Medical Center, Zrifin, Israel
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 1, 2013
Primary Completion (Actual)
March 1, 2017
Study Completion (Actual)
March 1, 2017
Study Registration Dates
First Submitted
December 4, 2013
First Submitted That Met QC Criteria
December 5, 2013
First Posted (Estimate)
December 10, 2013
Study Record Updates
Last Update Posted (Actual)
April 18, 2018
Last Update Submitted That Met QC Criteria
April 16, 2018
Last Verified
March 1, 2016
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- OS-BCC-P2-01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on BCC
-
Pulse Biosciences, Inc.CompletedBCC | BCC - Basal Cell Carcinoma | Excision MarginUnited States
-
Memorial Sloan Kettering Cancer CenterActive, not recruitingBasal Cell Carcinoma | Nodular Basal Cell Carcinoma | Superficial Basal Cell Carcinoma | BCC | BCC - Basal Cell Carcinoma | Basal Cell CancerUnited States
-
BiosceptreTKL Research, Inc.CompletedCarcinoma, Basal Cell (BCC)
-
Vejle HospitalNot yet recruitingSkin Diseases | Eyelid Diseases | Eyelid Tumor | BCC | BCC - Basal Cell Carcinoma
-
University of NottinghamNottingham University Hospitals NHS Trust; Circle Nottingham NHS Treatment...Not yet recruitingCarcinoma, Basal Cell | Intraoperative BCC Detection by Fast Raman Device
-
Carmel Medical CenterUnknownBasal Cell Carcinoma (BCC)Israel
-
University of AleppoAleppo University HospitalRecruitingBasal Cell Carcinoma | BCCSyrian Arab Republic
-
Biofrontera Bioscience GmbHAccovion GmbHCompletedBasal Cell Carcinoma (BCC)Germany
-
Stanford UniversityCompletedSkin Cancer | Basal Cell Carcinoma (BCC)United States
-
Seton Healthcare FamilyUniversity of Texas at Austin; Dell Medical School at The University of Texas...WithdrawnBasal Cell Carcinoma (BCC) | Squamous Cell Carcinoma (SCC)
Clinical Trials on Oshadi D & Oshadi R
-
Oshadi Drug AdministrationCompletedCancer | Metastasis | TumorIsrael
-
Oshadi Drug AdministrationSuspended
-
Oshadi Drug AdministrationCompletedLupus Erythematosus, SystemicIsrael
-
Oshadi Drug AdministrationUnknownCarcinoma, Non-Small-Cell LungIsrael
-
Oshadi Drug AdministrationSuspendedAcute Myeloid Leukemia | Lymphoid Leukemia
-
Oshadi Drug AdministrationCompletedDiabetes Mellitus, Insulin-Dependent, 1Israel
-
Oshadi Drug AdministrationCompletedDiabetes Mellitus | Insulin-Dependent | Type 1Israel
-
Oshadi Drug AdministrationCompleted
-
Assistance Publique - Hôpitaux de ParisCompletedHealthy VolunteersFrance
-
Johns Hopkins UniversityNational Institute of Allergy and Infectious Diseases (NIAID)Not yet recruiting